Financhill
Back

Halozyme Therapeutics 10K Form

Sell
48

HALO
Halozyme Therapeutics

Last Price:
38.61
Seasonality Move:
4.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive HALO News And Ratings

See the #1 stock for the next 7 days that we like better than HALO

HALO Financial Statistics

Sales & Book Value

Annual Sales: $829.25M
Cash Flow: $99.76M
Price / Cash Flow: 13.88
Annual Sales: $0.66
Price / Book: 58.44

Profitability

EPS (TTM): 2.11000
Net Income (TTM): $281.59M
Gross Margin: $636.89M
Return on Equity: 195.64%
Return on Assets: 15.68%

Halozyme Therapeutics Earnings Forecast

Key Halozyme Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 23 years for HALO is 76.80%.
  • The Selling, General & Administrative Expenses for HALO have been equal to 17.99% of Gross Profit Margin.
  • The Research & Development expenses have been 9.21% of Revenue.
  • The Interest Expense is 6.66% of Operating Income.
  • The Net Earning history of HALO is 33.96% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 11 years.

Halozyme Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Current Symbol: HALO
CUSIP: 40637H
Website: halozyme.com

Debt

Debt-to-Equity Ratio: 17.89
Current Ratio: 6.64
Quick Ratio: 5.07

Price-to-Earnings

Trailing P/E Ratio: 18.39
Forward P/E Ratio: 8.47

HALO Technical Analysis vs Fundamental Analysis

Sell
48
Halozyme Therapeutics (HALO) is a Sell

Is Halozyme Therapeutics a Buy or a Sell?